公开(公告)号：WO1990001931A1

公开(公告)日：1990-03-08

申请号：PCT/US1989003180

申请日：1989-07-25

Applicant: GEORGETOWN UNIVERSITY

Inventor： GEORGETOWN UNIVERSITY ,  TALEBIAN, Abdolhossen ,  GREEN, Diana ,  HAMMER, Charles ,  SCHEIN, Philip, S.

IPC: A61K31/40

CPC classification number: C07D487/14

Abstract: The invention relates to certain derivatives of mitomycins A and C and the use thereof to treat bacterial infections and to suppress the growth of cancer cells. The invention also relates to processes for the preparation of the mitomycin derivatives of the invention.

Abstract translation: 本发明涉及丝裂霉素A和C的某些衍生物及其用于治疗细菌感染和抑制癌细胞生长的用途。 本发明还涉及制备本发明的丝裂霉素衍生物的方法。

公开(公告)号：WO1983003191A1

公开(公告)日：1983-09-29

申请号：PCT/US1983000383

申请日：1983-03-18

Applicant: GEORGETOWN UNIVERSITY

Inventor： GEORGETOWN UNIVERSITY ,  LEDLEY, Robert, S. ,  GOLAB, Thomas, J. ,  BUAS, Michael

IPC: A61B05/04

CPC classification number: A61B5/4863 ,  A61B3/02 ,  A61B5/0484 ,  A61B5/0496 ,  A61B5/486 ,  A61B5/7203

Abstract: A computerized electro-oculographic (CEOG) system with feedback control of test stimuli comprises an integrated system for automated administration of electro-oculographic tests and visual evoked response test to a patient, automated processing (32) of the results derived from such tests, and automated feedback control (10, 26) of the test stimuli in accordance with the processed test results. The CEOG system is responsive to operator selection (44) of desired stimuli to be administered as well as to operator specification of various test stimuli characteristics, for automatically administering to the patient the test stimuli having the desired characteristics. Electrode test data derived therefrom are immediately recorded (40, 42) on-line, and are immediately and automatically analyzed to provide critical information for immediate display (38) in acceptable format and in a very short period of time. The integrated CEOG system is especially noteworthy for its use of the analyzed test data to control and vary the test stimuli (16) administered to the patient in accordance with the analyzed tests data results.

Abstract translation: 具有测试刺激的反馈控制的计算机化电眼（CEOG）系统包括用于自动管理电眼测试和对患者的视觉诱发反应测试的集成系统，从这些测试得到的结果的自动处理（32），以及 根据加工的测试结果自动反馈控制（10,26）的测试刺激。 CEOG系统响应于操作者选择要施用的所需刺激物（44）以及操作者对各种测试刺激特征的指定，以便自动向患者施用具有所需特征的测试刺激物。 在线接收电极测试数据（40,42），并立即进行自动分析，以便在可接受的格式和非常短的时间内为立即显示（38）提供关键信息。 综合CEOG系统特别值得注意的是，根据分析的测试数据结果，使用分析的测试数据来控制和改变对患者施用的测试刺激（16）。

公开(公告)号：WO1998024454A1

公开(公告)日：1998-06-11

申请号：PCT/US1997021959

申请日：1997-12-02

Applicant: GEORGETOWN UNIVERSITY

Inventor： GEORGETOWN UNIVERSITY ,  WELLSTEIN, Anton ,  SCHULTE, Anke ,  LAI, Shoupeng ,  KURTZ, Andreas ,  CZUBAYKO, Frank ,  RIEGEL, Anna

IPC: A61K31/70

CPC classification number: C12N15/1136 ,  A61K38/00 ,  C12N2310/111

Abstract: It was found that the depletion of HERV-PTN mRNA prevents human choriocarcinoma growth, invasion and angiogenesis. Growth, invasion and angiogenesis of a tumor containing human endogenous retrovirus-pleiotrophin (HERV-PTN) sequences may be inhibited by administration of a choriocarcinoma inhibiting amount of PTN-targeted ribozymes. A ribozyme of the formula: '5-GTTGCAGGGCTGATGAGTCCGTTAGGACGAAATCTTACATC-3' was found to be particularly useful for this purpose.

Abstract translation: 发现HERV-PTN mRNA的消耗可以预防人绒毛膜癌的生长，侵袭和血管生成。 含有人内源性逆转录病毒 - 多潜养蛋白（HERV-PTN）序列的肿瘤的生长，侵袭和血管发生可以通过施用绒毛膜癌抑制量的PTN靶向核酶来抑制。 发现具有下式的核酶：'5-GTTGCAGGGCTGATGAGTCCGTTAGGACGAAATCTTACATC-3'对于此目的特别有用。

公开(公告)号：WO1997024364A1

公开(公告)日：1997-07-10

申请号：PCT/US1997000084

申请日：1997-01-03

Applicant: GEORGETOWN UNIVERSITY

Inventor： GEORGETOWN UNIVERSITY ,  WEISS, Richard, G. ,  LU, Liangde

IPC: C07J01/00

CPC classification number: C07J41/0005

Abstract: Gelators gel a variety of nonpolar and polar liquids. Moreover, gelation of various monomers with subsequent polymerization of the gelled monomers forms organic zeolites and membrane materials. An ionic gelator includes salts of compounds of formula (I), where R , R and R are the same or different hydrogen or organic groups including alkyl groups, alkenyl groups, alkynyl groups, aryl groups, arylalkyl groups, alkoxy groups, aryloxy groups; X is a Group IIIA or Group VA element; R is a steroidal group, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, an arylalkyl group, an alkoxy group or an aryloxy group; and Y is a Group IA or Group VIIA element or one-half of a Group IIA or VIA element, that is, a divalent counterion. The gelling agent composition may include a single isomer or mixtures of isomers of the formula (I). A non-ionic gelator also includes compounds of the formula (II): R R R X where R , R , R and X are defined as above.

Abstract translation: 凝胶胶凝胶各种非极性和极性液体。 此外，各种单体的凝胶化随后凝胶化单体的聚合形成有机沸石和膜材料。 离子凝胶剂包括式（I）化合物的盐，其中R 1，R 2和R 3是相同或不同的氢或有机基团，包括烷基，烯基，炔基，芳基， 芳基烷基，烷氧基，芳氧基; X是IIIA族或VA族元素; R 4是甾族基团，烷基，烯基，炔基，芳基，芳基烷基，烷氧基或芳氧基; 并且Y是IAA族或VIIA族元素或IIA族或VIA族元素的二分之一，即二价抗衡离子。 胶凝剂组合物可以包括式（I）的单一异构体或异构体的混合物。 非离子胶凝剂还包括式（II）的化合物：R 1 R 2 R 3 X其中R 1，R 2，R 3和X如上所定义。

公开(公告)号：WO1997011706A1

公开(公告)日：1997-04-03

申请号：PCT/US1996015467

申请日：1996-09-27

Applicant: GEORGETOWN UNIVERSITY

Inventor： GEORGETOWN UNIVERSITY ,  SPIEGEL, Sarah

IPC: A61K31/685

CPC classification number: A61K31/688 ,  A61K31/685

Abstract: It has now been found that, at certain concentrations, sphingosylphosphorylcholine (SPC) in solution can be used for wound healing at concentrations of from 0.1 mu M to 500 mu M. It has been found that at concentrations of 2 mu M to 10 mu M, very good results could be obtained. Compositions may be prepared using pharmaceutically acceptable carriers for topical application or for injection in or near the site of the wound.

Abstract translation: 现在已经发现，在一定浓度下，溶液中的鞘氨醇磷酰胆碱（SPC）可以用于0.1μM至500μM浓度的伤口愈合。已经发现，在浓度为2μM至10μM ，可以获得非常好的结果。 组合物可以使用药学上可接受的载体制备，用于局部施用或在伤口部位或其附近注射。

公开(公告)号：WO1997007792A1

公开(公告)日：1997-03-06

申请号：PCT/US1996013775

申请日：1996-08-23

Applicant: DEPARTMENT OF THE ARMY, US GOVERNMENT ,  GEORGETOWN UNIVERSITY

Inventor： DEPARTMENT OF THE ARMY, US GOVERNMENT ,  GEORGETOWN UNIVERSITY ,  WOOSLEY, Raymond ,  WESCHE, David ,  SCHUSTER, Brian

IPC: A61K31/135

CPC classification number: A61K31/137 ,  Y02A50/411 ,  Y10S514/895

Abstract: This invention provides a method of treating patients suffering from malaria whilst avoiding cardioarrhythmias, the improvement thereof comprising the administration of desbutylhalofantrine in place of halofantrine. Dosage of 500 mg every six hours for three doses on day one with repeat of that dosage on day 7 for a total dosage of 3000 mg is appropriate for most treatment purposes in adults. Desbutylhalofantrine may also be given at dosage of 50 to 1000 mg as a prophylactic measure. Dosage may be given daily or one day per week.

Abstract translation: 本发明提供了一种治疗疟疾患者同时避免心律失常的方法，其改进包括施用去丁基卤吗啉替代卤黄嘌呤。 对于大多数治疗目的，成年人大多数治疗目的适合于在第7天给予剂量为500mg /天的三次剂量，在第7天重复该剂量，总剂量为3000mg。 也可以以50至1000mg的剂量给予丁苯基吗啡蒽作为预防措施。 可以每天或每周一天给予剂量。

公开(公告)号：WO1997000683A1

公开(公告)日：1997-01-09

申请号：PCT/US1996010751

申请日：1996-06-24

Applicant: GEORGETOWN UNIVERSITY

Inventor： GEORGETOWN UNIVERSITY ,  CLARKE, Robert ,  TALEBIAN, Abdel, H. +di ,  GHIORGHIS, Alem ,  LEONESSA, Fabio ,  HAMMER, Charles

IPC: A61K31/57

CPC classification number: C07J41/005

Abstract: The present invention is directed to novel progesterone derivatives, as well as to pharmaceutical compositions thereof, and methods of treatment using the derivatives. More particularly, the invention relates to C7-substituted derivatives of the pregnene series. The present invention is directed to methods of treating multidrug-resistant tumors, and especially breast tumors, with novel C7-substituted progesterone analogs.

Abstract translation: 本发明涉及新颖的孕酮衍生物及其药物组合物，以及使用衍生物的治疗方法。 更具体地，本发明涉及孕烯系列的C7-取代的衍生物。 本发明涉及用新型C7-取代的孕酮类似物治疗多药耐药性肿瘤，特别是乳腺肿瘤的方法。

公开(公告)号：WO1996002257A1

公开(公告)日：1996-02-01

申请号：PCT/US1995008781

申请日：1995-07-18

Applicant: GEORGETOWN UNIVERSITY

Inventor： GEORGETOWN UNIVERSITY ,  COLLEY, Kenneth, J. ,  WELLSTEIN, Anton

IPC: A61K31/70

CPC classification number: A61K31/711 ,  A61K38/00 ,  C12N15/1136 ,  C12N2310/111 ,  C12N2310/315

Abstract: Antisense oligonucleotides that hybridize to segments of the mRNA corresponding to the cDNA for pleiotrophin inhibit synthesis of pleiotrophin in vitro and in vivo. Pharmaceutical compositions containing these oligonucleotides as the active ingredients also are disclosed.

Abstract translation: 与对应于多潜养蛋白的cDNA的mRNA片段杂交的反义寡核苷酸抑制体外和体内多潜养蛋白的合成。 还公开了含有这些寡核苷酸作为活性成分的药物组合物。

公开(公告)号：WO1994003170A1

公开(公告)日：1994-02-17

申请号：PCT/US1993007260

申请日：1993-08-03

Applicant: SEPRACOR INC. ,  GEORGETOWN UNIVERSITY

Inventor： SEPRACOR INC. ,  GEORGETOWN UNIVERSITY ,  YOUNG, James, W. ,  GRAY, Nancy, M. ,  WOOSLEY, Raymond, L. ,  CHEN, Yiwang

IPC: A61K31/445

CPC classification number: A61K45/06 ,  A61K31/445 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising a compound of formula (I): wherein Z is COOH, COOCH3 or CH2OH, or a pharmaceutically acceptable salt thereof, for use in an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, comprising administering a therapeutically effective amount of a compound of formula (I) to a human patient.

Abstract translation: 一种药物组合物，其包含式（I）化合物：其中Z为COOH，COOCH 3或CH 2 OH或其药学上可接受的盐，用于不引起任何明显心律不齐的抗组胺治疗，包括给予治疗有效的 式（I）化合物与人类患者的量。

公开(公告)号：WO1993007931A1

公开(公告)日：1993-04-29

申请号：PCT/US1992009153

申请日：1992-10-23

Applicant: GEORGETOWN UNIVERSITY

Inventor： GEORGETOWN UNIVERSITY ,  VERRIER, Richard, L.

IPC: A61M31/00

CPC classification number: A61N1/0587 ,  A61M25/01 ,  A61M2210/122 ,  A61N1/05 ,  A61N1/306

Abstract: A method for placing various types of catheters into the pericardial space takes advantage of the fact that the right auricle is a thin-walled, low-pressure structure which can be readily penetrated without damaging the pericardium or the epicardium. The method avoids surgical trauma and the risks of general anesthesia and infection. A catheter (202) is guided downstream through one of the venae cavae (204) to the right atrium (110). Once inside the right atrium (110), the catheter is passed into the right auricle (108). The wall at the apex (112) of the right auricle (108) is then pierced to gain access to the pericardial space (106). The method can be used to provide electrical stimuli to the heart, to pick up an ECG signal, to deliver pharmacologic agents to the heart, to improve vascularization, to remove pericardial fluid for analysis or pericardiocentesis, or to inject a radio-labelled or echo-sensitive dye into the pericardial space for precision fluid imaging.